ERBB2 and neoplasm: Among screen-detected cancers, 10.2% were HER2-positive, whereas 5.7% were of the triple-negative phenotype, compared with 16.7% HER2-positive/14.6% triple-negative tumor for interval cancers and 17.5% HER2 positive/8.8% triple-negative tumor for NRS.